Establishment of cherimic huPBL-SCID-HCC model in SCID mice by intraperitoneal injection of human peripheral blood monocytes

Objective To explore the feasibility of constructing cherimic huPBL SCID HCC model in SCID mice by intraperitoneal injection of human peripheral blood monocytes. Methods Human PBLs were isolated from peripheral blood of healthy donors and intraperitoneally injected into SCID mice at a dose of 2×10 7 cells/mouse. Simultaneously, 5×10 5 HepG2 cells in 0 2 ml were intracutaneously injected into the right flank of the mice. Two and 4 weeks later, CD3 expressin in PBMCs isolated from the mice were analyzed by FACS and human IgG in mouse blood was determined by ELISA. In week 4, splenic cells of the mice were prepared to determine cytotoxicity against HepG2 cells and detect human lymphocytes immunohisochemically in cryostat section. Results The tumorigenecity rate was 100% with latent period of 12 to 18 days. In the second and fourth week after injection, the content of human IgG in the mouse blood reached 69 8 μg/ml and 125 9 μg/ml and the ratio of CD3 + cells in the mouse blood was 10 5% and 3 5%, respectively. In the fourth week after the injection, cytotoxicity of the mouse spleen cells was 20 3% and existence of CD3 + cells in the mouse spleen was demonstrated immunohisochemically. Pathological examination showed tumor growth. Conclusions The huPBL SCID HCC model can be successfully established by combination of intraperitoneal injection of human peripheral blood monocytes and subcutaneous injection of liver cancer cells in SCID mice.